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PBiomarkers in Acute Aortic Dissection
and Other Aortic Syndromes
Aaron M. Ranasinghe, MD, Robert S. Bonser, MD
Birmingham, United Kingdom
Acute aortic syndromes have an incidence of 30 per million per annum and a high mortality without definitive
treatment. Survival may relate to the speed of diagnosis. Although pain is the most common symptom, there is
a large fraction of patients in whom the diagnosis may be mistaken or overlooked. Currently, a high index of
clinical suspicion is the chief prompt that diverts a patient into a definitive algorithm of imaging investigations.
Although there is no point-of-care biochemical test that can be reliably used to positively identify dissection,
biomarkers are available that could accelerate the diagnostic pathway and thereby expedite treatment.
(J Am Coll Cardiol 2010;56:1535–41) © 2010 by the American College of Cardiology Foundation
































dcute aortic dissection (AAD) is the most common thoracic
ortic emergency and may be rapidly fatal without early
iagnosis and appropriate management (1,2). Symptoms,
igns, electrocardiograms (ECGs), and chest X-rays lack
ensitivity and specificity (1). Diagnosis is therefore not
mmediate; definitive confirmatory investigation may not
vailable in the emergency room (ER), and the varied
resentation allows the diagnosis to be missed, misdiag-
osed, or overlooked in up to 40% of cases (3), sometimes
nly being established at post-mortem (4,5).
The 2 common classifications of AAD are the DeBakey
nd Stanford classifications. The Stanford type A and
eBakey I and II variants involve the ascending aorta,
hereas type B dissection (DeBakey III) involves the
escending aorta only. Acute type A dissection is highly
ethal, but a rapid diagnosis may allow life-saving surgical
epair. Untreated mortality may approximate 1% to 2%/h
ollowing symptom onset with the majority of patients
uccumbing within 30 days (6–8). Surgical repair trans-
orms the high mortality risk to a greater than 70% survival
hance in the short term. This survival advantage of surgery
ontinues in the longer term with outcomes vastly superior
o those achieved by conservative management (9).
The initiating event of AAD may relate to medial
ematoma bursting inwards through the media or the
evelopment of an intimomedial tear due to shear forces
ithin the aortic lumen with propagation of a cleavage line
ithin the media for a varying extent of the aortic wall
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010, accepted January 25, 2010.4,10). Other acute aortic syndromes (AAS), intramural
ematoma, and deep penetrating ulcers may have similar
resentations and prognosis but may cause less medial
isruption (4). All aortic syndromes generate a vascular
edial injury, and some generate an additional intimal
esion. Exposure of the media to blood elements initiates the
oagulation cascade and generates a consumption coagu-
opathy. The degree of this coagulopathy will depend upon
he surface area of tissue exposure and whether false luminal
hrombosis occurs.
For all AAS, reduction in overall patient mortality might
e best achieved by shortening the time from symptoms to
reatment. Notwithstanding several recommendations and
uidelines, the evidence suggests that definitive manage-
ent is delayed for several hours while diagnostic evaluation
s completed. Approximately 75% of patients with acute
issection have their initial diagnosis made in a nonspecial-
st hospital (11). The time from initial symptoms to hospital
resentation is approximately 1 to 2 h, but the time to
iagnosis varies considerably (12). Fifty percent of patients
ave a time to diagnosis of 6 h in Europe and 15 h in
he U.S.; 75% of patients have diagnostic times 3 to 4 h
11). In type A dissection, the time duration between
resentation and definitive management is 12 h in the
ajority of patients and has been reported as being 24 h
n 20% to 50% in some series (9,13,14). In type B dissection,
he mainstay of treatment is initial medical therapy with
ntihypertensive management. Patients presenting with
typical symptoms are at increased risk of in-hospital
ortality, which may be related to diagnostic delay, pro-
onging the institution of treatments that may affect the
isease’s natural history, particularly dissection propagation
15). Delays in instigating blood pressure control in type B
issection may be 24 h after the initiating event, a period
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icance of accelerating diagnosis is
evident.
Diagnostic delay is exacerbated
by nonclassical presentations that
do not evoke clinical suspicion
such as painless malperfusion phe-
nomena, dypsnea due to heart fail-
ure or pleural effusion, troponin
positivity, acute coronary syn-
drome–like ECG, limb ischemia,
or abdominal pain, all of which are
associated with longer in-hospital
diagnostic times (14,16,17).
The challenge is therefore to
accurately diagnose the condition
as early as possible. The primary
presentation of AAD to the ER
is most commonly an elderly
ale, with hypertension and sudden onset chest pain (1),
nd the much more common acute coronary syndrome is an
mportant differential diagnosis. Any lack of suspicion of
AD will fail to trigger investigation, delaying diagnosis
3). In the absence of a rapid, accurate, and readily available
iagnostic test, the current diagnosis of AAD requires
efinitive imaging such as computed tomography (CT),
ransesophageal echocardiography (TEE), or magnetic res-
nance imaging (MRI), (18) but the use of each investiga-
ion is based on an index of clinical suspicion, and each
ncurs a further logistical delay in patient management.
Myocardial ischemia has the diagnostic advantages of the
CG and troponin estimation, allowing risk stratification
nd emergency treatment. AAS have no such rapidly
vailable diagnostic tools. However, the higher and early
ortality of these conditions appeals for a rapid, sensitive,
nd specific point-of-care diagnostic test that could be
ndertaken as a point-of-care assessment in the ambulance
r ER, allowing direction towards imaging and definitive
reatment. Other advantages would include:
. An ability to reliably exclude an AAS, allowing diversion
of investigative resources in different directions.
. An ability to place an AAS as a likely diagnosis,
accelerating the patient’s progression to treatment in an
appropriate medical center.
. An enhanced high index of suspicion of an AAS,
allowing pre-formal diagnosis delivery of blood pressure–
reducing and anti-impulse therapy.
. Prevention of inappropriate therapy (e.g., thrombolysis
and antiplatelet agents).
hus, there is a need for a specific biomarker test or array
hat can reliably include or exclude AAD and other AAS as
diagnostic possibility. Such a test would necessarily have
eed to distinguish other possible diagnoses, in particular
Abbreviations
and Acronyms
AAD  acute aortic
dissection
AAS  acute aortic
syndrome(s)
AMI  acute myocardial
infarction
CRP  C-reactive protein
DD  D-dimer(s)
ECG  electrocardiogram
ER  emergency room
PE  pulmonary embolism
sELAF  soluble elastin
fragments
smMHC  smooth muscle
myosin heavy chainhe possibility of troponin-positive dissections in the pres- pnce of coronary malperfusion and acute abdomen biomar-
ers when visceral malperfusion occurs.
otential Biomarkers in AAD
s dissection is a disease of the aortic medial layer, the
earch for biomarkers has been concentrated upon markers
eflecting injury to vascular smooth muscle (smooth muscle
yosin), the vascular interstitium (calponin), the elastic
aminae (soluble elastin fragments [sELAF]) of the aorta, or
econdary phenomena due to exposure of blood to nonin-
imal vascular surfaces (D-dimers [DD]) (19). For a bi-
marker to be acceptable for the paramedic or physician to
mploy, it must fulfill a number of criteria (20):
• Widely commercially available;
• Easy to use and fast;
• High sensitivity (identify all cases of AAD);
• High specificity (identify all cases that are not AAD);
• Release should be temporally related to presentation of
event; and
• Have an acceptable cost.
o current biomarkers fit this profile, but we review the
trengths and weaknesses of biomarkers studied to date.
iomarkers for diagnosis of AAD. SMOOTH MUSCLE
YOSIN HEAVY CHAIN (smMHC). Smooth muscle myosin is
major component of smooth muscle. It is also present in
terine and intestinal smooth muscle and potentially could
e elevated in conditions involving these systems. Prelimi-
ary experience by Katoh et al. in 1995 (21,22) suggested
hat smMHC is elevated within the first 24 h following
AD. Suzuki et al. (23) enrolled 27 patients with AAD
type A, n  16), investigated 6.0  1.3 h after symptom
nset. Serum samples were obtained at 12-h intervals for the
rst 3 days and then at 24-h intervals for the next 7 days, for
nalysis of smMHC. Peak levels of smMHC were noted at
nitial testing with a rapid reduction in the first 24 h (Fig. 1).
t a cutoff value of 2.5 ng·ml1, the sensitivity of the assay
as 90% and 85% at 12 and 24 h, respectively. All patients
ith values less than the cutoff value had type B or DeBakey
II pathology, and this may be related to differential
xpression in different parts of the aorta. Patients with acute
yocardial infarction (AMI) did not demonstrate any
ncrease in smMHC levels in this group of patients (23).
As the initial assay time for smMHC was 5 h, the authors
eveloped a rapid 30-min assay (24) and tested this in a
ulticenter study recruiting 95 patients with AAD (pre-
enting within 24 h of symptom onset), 48 with AMI, and
31 healthy volunteers. Levels of smMHC were signifi-
antly higher for patients with AAD compared with healthy
olunteers, and values were highest in patients presenting
ithin the first 3 h. A significant reduction in levels
ccurred after 3 h, diminishing sensitivity. At a cutoff level
f 2.5 ng·ml1, sensitivity was 90.9% in the first 3 h, 72.4%
n the subsequent 3 h, and 30.3% thereafter. When com-
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November 2, 2010:1535–41 Biomarkers in Aortic Dissectionh following AMI, the assay had a specificity of 83% at the
.5 ng·ml1 cutoff level. Levels of smMHC greater than 10
g·ml1 demonstrated a specificity of 100% for detecting
AD. Levels were significantly higher in proximal com-
ared with distal lesions; and in patients with distal lesions
DeBakey III), even if presenting within the first 3 h of
ymptom onset, smMHC levels were not 2.5 ng·ml1
24). smHMC is not currently available as a point-of-care
est.
In summary, smMHC is elevated in the first hours
ollowing AAD, but levels rapidly decrease in the first 24 h.
t is not elevated in the setting of AMI. The smMHC
levation is greater in proximal versus distal dissection. This
nvestigation could have utility if administered at initial
resentation but rapidly loses sensitivity as time after symp-
om onset increases.
ALPONIN. In cardiac muscle, contraction is regulated by
he troponin-tropomyosin system, allowing the develop-
ent of troponin assays as sensitive and specific biomarkers
f myocardial injury (25,26). Contraction of smooth muscle
s regulated primarily by the reversible calcium-calmodulin–
ependent phosphorylation of myosin; however, contraction
an be modulated by other signal transduction pathways,
ne of which involves the thin filament-associated protein
alponin (27). Within vascular smooth muscle, calponin, a
4-kDa protein that is a troponin counterpart of smooth
uscle (28), has previously been isolated and purified (29).
alponin has 3 isoforms: basic (also termed h1), acidic, and
eutral (termed h2), with the basic isoform being the most
bundant and specific to smooth muscle. This protein has
ecently been the focus of recent study in AAD (30). After
eveloping calponin assays for all 3 isoforms, 217 patients
Figure 1 The Time Course of smMHC Levels in
Patients With Aortic Dissection (n  27)
Peak levels are at symptom onset. Thereafter, a rapid decline is noted over
time (23). Reprinted, with permission, from Suzuki et al (23). smMHC 
smooth muscle myosin heavy chain.ith a high suspicion of AAD (high enough to request lefinitive imaging by which confirmation of diagnosis was
btained) were studied. Of the total study population, 59
27.2%) had confirmed AAD (72.9% type A), 44.9% had
ardiac disease, 10.8% thoracic aneurysm (nondissecting),
.9% pulmonary embolism, and 42.4% had an uncertain
iagnosis but not AAD. Acidic calponin showed a 2-fold
ncrease for all dissections within the first 6 h of symptom
nset (more notable for type A versus B). In both the 6- to
2-h and 12- to 24-h time periods, type A dissections
emonstrated acidic calponin levels continued to increase,
lbeit with a reduced rate of rise. Within the first 6 h, basic
alponin demonstrated a greater than 3-fold increase for all
issections (similar for both type A and B). In the 6- to 12-h
eriod, type A dissections still demonstrated a greater than
-fold increase (there was, however, a drop-off for type B).
oth type A and B were still elevated at 12 to 24 h but
ontinued to fall compared with previous time intervals.
eutral calponin did not demonstrate any elevation at any
f the time points studied. None of the 3 isoforms of
alponin were elevated at any of the examined time points in
on-AAD patients.
During the first 6 h using an optimal value of 2.3 ng·ml1
acidic) and 159 ng·ml1 (basic) resulted in a sensitivity of
0% and 63% and specificity of 87% and 73% for acidic and
asic calponins, respectively. For the initial 24-h period,
sing values of 2.3 ng·ml1 (acidic) and 139 ng·ml1 (basic)
ed to a sensitivity of 58% and specificity of 72% (acidic) and
sensitivity of 50% and specificity of 66% (basic). Predictive
alues (negative and positive, respectively) were 0.84 and
.56 in the first 6 h, and 0.84 and 0.41 in the initial 24 h for
cidic calponin. For basic calponin, predictive values were
.86 and 0.44 in the first 6 h, and 0.80 and 0.33 in the initial
4 h. A strength of this study was that it contained patients
n whom a diagnosis of AAD was being actively pursued
and not utilizing healthy individuals), a situation more
pplicable to the ER and biomarker validation. Calponin
ssays are not currently available as point-of-care tests.
In summary, calponin has 3 isoforms, the basic isoform
eing the most extensively studied. Its levels are elevated in
he setting of both proximal and distal aortic disease within
he first 24 h. Although calponin has satisfactory negative
redictive value during the first 24 h, its positive predictive
alue is poor. The high specificity of acidic calponin in the
arly period after symptom onset could be of utility if
dministered as part of a biomarker array at presentation but
ould require further development and refinement of avail-
ble assays as point-of-care tests.
ELAF. Elastin is one of the main structural components of
he arterial wall (31), and mature elastin is composed of
oluble elastin subunits. As one of the main pathological
eatures of the aortic media in AAD is elastin lamellar
isruption (32,33), elastin degradation products (sELAF)
ould potentially be released into the circulation at the time
f AAD (3). Shinohara et al. (34) developed an enzyme-
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Biomarkers in Aortic Dissection November 2, 2010:1535–41entration of sELAF in serum. The study comprised 25
atients with AAD, 50 patients with AMI, 20 patients with
hest pain (AAD and AMI excluded), 40 nontreated
ypertensive subjects, and 474 healthy controls. The first 3
roups were all recruited to the study within 48 h of
ymptom onset. In 474 healthy controls, sELAF was
emonstrated to increase with advancing age, but no gender
ifferences were noted. In patients with AAD, sELAF
mean  SD) was 114.7  56.9 ng·ml1 compared with
6.1  14.9 ng·ml1, 47.3  13.5 ng·ml1, and 47.7 
2.3 ng·ml1 for AMI, chest pain (AAD/AMI ex-
luded), and nontreated hypertensive groups, respectively
Fig. 2). With a cutoff point for positivity set at 3
tandard deviations above the mean in healthy subjects at
ach age, 16 patients (64.0%) with AAD were positive,
ith a specificity of 99.8%. The positive and negative
redictive values were 94.1% and 98.1%, respectively.
For patients with AAD and a patent or partially throm-
osed false lumen, 88.9% were positive for sELAF. In the
roup of patients with a completely thrombosed false
umen, sELAF assays were negative, a clear limitation of the
arker. The difference in sELAF between patent/partially
ccluded and occluded false lumens was 135.4  53.2
g·ml1 versus 60.3  15.6 ng·ml1, p  0.005, respec-
ively. However, when serial sELAF serum levels were
easured (n 5, open/partially occluded), results suggested
hat sELAF remain elevated for a period of 72 h (34).
Figure 2 Serum sELAF Levels in Patients With AAD or AMI
The continuous lines represent mean and dashed lines up to 4 SDs above
mean values for healthy controls. Open squares indicate AAD with patent false
lumen, closed squares indicate AAD with thrombosed lumen. Open triangles
indicate AMI patients. Reprinted, with permission, from Shinohara et al. (34).
AAD  acute aortic dissection; AMI  acute myocardial infarction; sELAF 
soluble elastin fragments.soluble elastin fragment assays are not currently available as
point-of-care tests.
In summary, sELAF elevation is sustained for quite long
eriods (up to 72 h) post-AAD. It has excellent positive and
egative predictive values for AAD with perfused false
umen, but levels are reduced with partial and negative with
omplete false lumen thrombosis. It could however have
tility as part of a biomarker array for AAD.
-REACTIVE PROTEIN (CRP). CRP is an acute phase protein
roduced in the liver that is nonspecifically elevated in a
umber of conditions (including AAD) in response to
nflammatory processes. In 255 patients admitted with
ymptomatic aneurysmal disease or AAD, Schillinger et al.
35) measured CRP levels on admission to the ER. CRP
evels were temporally related to onset of symptoms, with
atients with a shorter duration of pain (under 8 h) having
significantly lower CRP than those with longer symptom
nset (24 h). Both CRP and white blood cell counts are
igher in chest pain patients with dissection versus other
iagnoses, but differences are not sufficient to affect the
iagnostic algorithm.
-DIMER (DD). DD is a fibrin degradation product, present
n the circulation following fibrinolysis of thrombus. It was
rst introduced in the 1990s as a diagnostic aid for thro-
oboembolic disorders such as deep venous thrombosis and
ulmonary embolus, for which they have a high negative
redictive value but a low specificity (36,37). Elevated levels
f DD can be found in a number of disease states, including
alignancy, disseminated intravascular coagulation, recent
rauma or surgery, deep venous thrombosis, PE, and AAD.
ollowing an incidental observation, Weber et al. (38)
nvestigated the relationship of elevated DD levels and
AD. They prospectively evaluated DD levels in 10 pa-
ients with confirmed AAD (as well as 14 retrospective
ases) and compared these with 35 consecutive admissions
ith acute chest pain without AAD. Out of the 35 controls,
0 (57.1%) had an acute cardiac cause for chest pain, and
nly 1 patient had a diagnosis of PE. DD levels were
ositive in all AAD patients, and values were higher in more
xtensive disease. With a cutoff value of 0.5 g·ml1, DD
ad a sensitivity of 100% and a specificity of 68.6% (38) in
ositively detecting AAD.
Eggebrecht et al. (39) studied 64 consecutive chest pain
atients (16 AAD, 16 PE, 16 AMI, 16 noncardiac), assessing
D levels within 48 h of symptom onset. DD levels were
levated in all patients with AAD, significantly so versus AMI
nd noncardiac chest pain, but no different when compared
ith PE. A negative correlation was noted between the DD
alue and time of symptom onset. With a cutoff value of 0.62
g·ml1, sensitivity and specificity were 100% and 73%,
espectively. At a cutoff value of 0.5 g·ml1, sensitivity and
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November 2, 2010:1535–41 Biomarkers in Aortic DissectionThere are a number of different assays available to test
D levels, and it is important that cutoff values and
ensitivities are reported for individual assays. Akutsu et al.
ompared a rapid DD test (which returns a DD value from
hole blood within 10 min) with a standard latex aggluti-
ation assay for screening clinically suspected AAD (40). In
he study cohort of 78 patients, 30 had AAD, and of the
emaining 48, 7 (14.6%) had nondissecting aneurismal
isease and 2 (4.1%) had PE. All patients with AAD had a
D value 0.5 g·ml1, and the new, rapid bed-side test
orrelated well with the standard latex agglutination assay.
ith a cutoff value of 0.5 g·ml1, sensitivity was 100%
nd specificity 54% (40). In an attempt to improve speci-
city, Akutsu et al. next looked at DD estimation in
onjunction with hypertension on admission (systolic blood
ressure greater than 180 mm Hg). Although this combi-
ation of variables improved the specificity (96%) with a
ositive predictive value of 86%, sensitivity fell to 40% (40).
In a single-center, retrospective case-control study, Ohl-
ann et al. (41) also assessed the usefulness of measuring
D in managing patients with AAD. Out of 94 patients
ith AAD, 93 had levels 0.4 g·ml1. DD levels were
ositively correlated with the anatomical extent of dissection
nd in-hospital mortality. With a cutoff value of 0.4
g·ml1, sensitivity and specificity were 99% and 34%,
espectively. In a multivariate analysis, independent predic-
ors of in-hospital mortality were pericardial effusion (odds
atio [OR]: 6.80 [95% confidence interval (CI): 1.87 to
7.60]), female sex (OR: 4.96 [95% CI: 1.39 to 19.95]), and
D levels 5.2 g·ml1 (OR: 5.38 [95% CI: 1.27 to
0.87]) (41). Weber et al. (42) have also reported the
rognostic relevance of DD measurement in a cohort of 27
atients with AAD. Nonsurvivors in patients with AAD
ere demonstrated to have significantly higher DD levels
han survivors in both patients who were surgically or
edically managed.
Sodeck et al. (43) performed a systematic review and
rospective cohort study of use of DD as a biomarker in
xcluding AAD. In a total of 16 studies reviewed (n 437),
nly 15 of 437 (3.4%) patients with AAD were DD
egative. Their meta-analysis demonstrated that DD
ielded a high sensitivity and negative likelihood ratios
with narrow CIs), implying that a negative DD is likely to
xclude the diagnosis of AAD; however, pooled specificities
nd positive likelihood ratios did not increase the ability to
iagnose AAD. In their cohort of 65 patients with a median
interquartile range) symptom onset of 4.8 (2.4 to 16) h, the
ensitivity of initial DD levels for excluding the diagnosis of
AD at cutoff values of 0.1, 0.5, and 0.9 g·ml1 were 100%,
8%, and 86%, respectively (43).
Recently, the IRAD-Bio (International Registry of Acute
ortic Dissection Substudy on Biomarkers) study reported
n the use of DD assessment in AAD diagnosis (44). The
tudy recruited 220 patients with clinical suspicion of AAD
ithin the first 24 h following symptom onset (Fig. 3). Of
he 220 patients, 87 (39.5%) had a radiographically con-Figure 3 DD Levels From Time of Symptom Onset
in Patients From the IRAD Biomarkers Study
D-dimer (DD) levels were 5- to 10-fold greater for patients with dissection com-
pared with other diagnoses in the first 6 h. In the 12- to 24-h period, a comparable
elevation of DD was noted in patients with a diagnosis of pulmonary embolus. (A)
0- to 6-h time period; (B) 6- to 12-h time period; and (C) 12- to 24-h time
period. Reprinted, with permission, from Suzuki et al. (44). AD(A)  positive
for aortic dissection, type A; AD(B)  positive for aortic dissection, type B;
IRAD  International Registry of Acute Aortic Dissection; MI  myocardial
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Biomarkers in Aortic Dissection November 2, 2010:1535–41rmed diagnosis of AAD (type A, n  64). Of the
emaining 133, diagnoses were: myocardial ischemia, 83
37.7%); PE, 5 (2.3%); and uncertain (AAD excluded)
iagnosis, 45 (20.5%). DD values demonstrated favorable
verall diagnostic performance (area under the curve on
eceiver operating characteristic curve analysis) compared
ith the control group (0.84) and when analyzed according
o the diagnosis of angina (0.93), uncertain diagnosis (0.82),
I (0.81), and PE (0.65). At a cutoff value of 0.5 g·ml1
ersus controls, sensitivity and specificity were 96.6% and
6.6%, respectively. Compared with angina, uncertain di-
gnosis, MI, and PE, specificities were 62.2%, 44.4%,
9.1%, and 20.0%, respectively (44). Thus, DD assessment
ay have an important role in the investigational triage of
atients with suspected AAD.
However, despite the excellent sensitivities associated with
D estimation in the aforementioned studies, some patient
ubgroups can generate a false negative result (i.e., a low or
quivocal DD level in the presence of AAD). Hazui et al. (45)
ound that absolute DD values are lower in patients with
hrombosed false lumen, shorter dissection lengths, and
ounger age groups, and such patients could be misdiagnosed
f DD assays were used in isolation. Reduced sensitivity and
bsolute DD levels in patients with thrombosed false lumen
ave also been reported by Akutsu et al. (40).
In summary, DD levels have an excellent sensitivity for
he detection of AAD and could be used to triage patients
owards definitive imaging for diagnosis of AAD even in the
resence of troponin positivity. The test is easily employed
ithin the ER. When DD elevation is present, an impor-
ant differential diagnosis is acute PE. However, as suspi-
ion of both AAD and acute PE direct the patient towards
efinitive imaging studies, this lack of specificity is not
ecessarily a disadvantage. However, as DD may lack
ensitivity for certain AAD subtypes, a high index of clinical
uspicion should overrule equivocal DD levels in directing a
atient towards definitive imaging.
ummary of Biomarkers Used in AAD
here are a number of biomarkers that have potential to
ccelerate diagnosis in AAD, but none is yet completely
alidated, and combination biomarker arrays have yet to be
nvestigated. Each have difficulty in recognizing patients
ith a thrombosed false lumen or limited disease extent, and
ost have limited half-lives. Of those discussed, there is
ittle experience with other AAS, intramural hematoma,
nd acute penetrating ulcers that have not progressed to
issection. Although smMHC demonstrates good early
ensitivity for detection of AAD, levels quickly fall and are
educed in more distal disease. Experience with calponin is
imited, but assays need further development to improve
ensitivity and specificity. Levels of sELAF remain elevated
or up to 72 h and are better at detecting proximal than
istal disease; however, sELAF is not detected in the
resence of a thrombosed false lumen. Estimation of DD aas an excellent sensitivity for AAD, but moderate speci-
city, and may be helpful in imaging investigation triage.
owever, false negative low DD levels have been reported
n patients with thrombosed false lumen, less extensive
isease, and younger age groups. Physicians should be aware
hat DD assessment cannot completely rule out dissection
r other AAS, and that in equivocal cases with a high index
f clinical suspicion, imaging should still be rapidly per-
ormed if these diagnoses are not to be overlooked.
hat Is Needed?
he management of AAS patients is dependent upon their
natomical characterization and type and presence of com-
lications, including rupture, rupture risk, and malperfusion
henomena; imaging, therefore, plays a key role. The
mportance of a diagnostic biomarker in AAS is to allow
riage of patients who should undergo rapid imaging,
llowing the prompt initiation of treatment algorithms.
his would reduce delays in diagnosis and increase the
umber of patients diagnosed and treated, potentially im-
roving the prognosis of patients with these conditions. The
ata presented suggest that there are a number of candidate
iomarkers that could prove of value particularly if used in
ombination. Consider, for instance, a patient with type A
issection complicated by coronary malperfusion whose
ymptomatology and preliminary investigations would be
onsistent with acute ST-segment elevation myocardial
nfarction. Such an AAD patient should not receive high-
ose antiplatelet agents, undergo thrombolysis, or proceed
o primary angioplasty, but rather should undergo AAD
maging and prompt surgical repair. Although a positive
roponin study might be expected, a course of investigation
hat included DD and vascular smooth muscle injury
arker assessment might better direct this patient manage-
ent. Much more information is needed. Not only do we
eed identification and characterization of further candidate
iomarkers, we also need validation in prospective cohorts
f patients presenting with chest pain. Most biomarker
ssessment has been undertaken in patients in whom the
iagnosis is known, and results have often been compared
rom normal control patients without chest pain morbidi-
ies. As the relative frequencies of AAS to acute coronary
yndromes approximate 1 in 1,000, prospective studies to
llow earlier diagnosis are difficult to design but nevertheless
ecessary. Recent reports have demonstrated that such
tudies are possible, and more are urgently required (44).
onclusions
here is currently no single biomarker that can positively
dentify AAD or other AAS. Of those studied, DD analysis
as sufficient predictive value to facilitate imaging investi-
ation triage with some caveats. Research is necessary to
urther determine the role of DD assessment and to discover
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n the diagnostic algorithm.
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